NCT06375993: A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
- State
- Under way
- Phase
- Phase 1
- People
- 180 planned
- Started
- 10 Nov 2024
- Primary completion
- Dec 2026
- Arms
- ADI-001 Dose Escalation, ADI-001 Dose Extension, ADI-001 Dose Expansion
- Results
- None posted
- 19 Apr 2024: Trial registered
- 10 Nov 2024: Trial started